Hormone FDA Approved

Vosoritide

An FDA-approved C-type natriuretic peptide analog marketed as Voxzogo for achondroplasia.

CNP AnalogFDA ApprovedAchondroplasiaRare Disease

Also referenced as: Voxzogo

Public product evidence No certificate records are bound to a tracked Vosoritide product page A record counts here only when a vendor publishes a certificate against one of its own tracked Vosoritide product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Research area
Hormone signaling research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Body systems
Muscle & bone · Hormones

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
1

Voxzogo

Signal depth
High

FDA label signal · 18 trials · 127 PubMed results

Established
Research evidence

Vosoritide is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Vosoritide has 10 name-matched clinical trials (highest phase: Phase 3) and 127 PubMed-indexed publications and holds an FDA drug label. Human trials are registered but none have posted results yet.

FAERS (approved drug): 1
Human data
Approved drug
Trial quality
Randomized
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals
PHASE2/PHASE3 · Randomized Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia PHASE3 Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia PHASE3 · Randomized Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia The Lancet · 205 citations Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial Genetics in Medicine · 102 citations Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study The Lancet Child & Adolescent Health · 69 citations Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What vosoritide is

Vosoritide is a C-type natriuretic peptide analog marketed as Voxzogo.

Why it matters

It brings another important approved peptide therapy into the library and broadens the site beyond the same few internet-famous compound classes.

Regulatory context

Vosoritide is FDA approved in the United States.

Practical reading note

Vosoritide is a good reminder that approved peptide therapeutics span far beyond weight loss, anti-aging, or performance claims.